news
RNA-binding proteins play important role in motor neurone disease
30 October 2015 | By Victoria White
The discovery about the FUS protein could be a major milestone on the path to a treatment for both motor neurone disease and dementia...
List view / Grid view
Dementia
news
Launch of Dementia Discovery Fund to deliver new dementia treatments by 2025
21 October 2015 | By Kate Douetil
This innovative new global investment fund has gained support from a wide variety of investors, including the UK Government’s Department of Health (DoH), Alzheimer’s Research UK and world-leading major pharmaceutical companies Biogen, GlaxoSmithKline, Johnson & Johnson, Lilly, Pfizer and Takeda...
news
UCL and Takeda to identify targets for neurodegenerative diseases
14 October 2015 | By Victoria White
The three-year collaboration will focus on mechanistic approaches for the identification of genes or signalling pathways that modify neurodegenerative disease processes affecting neuronal health...
news
Astex Pharmaceuticals joins The Dementia Consortium
12 October 2015 | By Victoria White
The Dementia Consortium is a £3.5m drug discovery collaboration between Alzheimer’s Research UK, MRC Technology, Eisai, Lilly and now Astex...
news
Gene therapy prevents disease effects in Parkinson’s disease model
9 October 2015 | By Victoria White
Researchers reported that treatment with IFNβ-gene therapy successfully prevented neuronal death and disease effects in an experimental model of the disease...
news
Cancer drug RGFP966 appears to sharpen memory
5 October 2015 | By Victoria White
Rats given RGFP966 were more attuned to what they were hearing and were able to retain and remember more information...
news
Dementia Consortium funds project focusing on ALS and FTLD
16 September 2015 | By Victoria White
A team at the International Centre for Genetic Engineering and Biotechnology (ICGEB) will join forces with MRC Technology to take on the project...
news
UMG and MRC Technology collaborate to develop Alzheimer’s therapy
28 July 2015 | By Victoria White
UMG and MRC Technology are to collaborate to develop a novel therapy for neurodegenerative diseases based on antibody targeting amyloid beta peptides 4-x...
news
Scientists see iron-containing microglia in Alzheimer’s brains
21 July 2015 | By Victoria White
Examining post-mortem tissue from the brains of people with Alzheimer's disease, researchers identified iron-containing microglia in the hippocampus...
news
Genetic markers linking risk for type 2 diabetes and Alzheimer’s identified
20 July 2015 | By Victoria White
Certain patients with type 2 diabetes may have specific genetic risk factors that put them at higher risk for developing Alzheimer’s disease...
news
Probiodrug funds Brigham and Women’s Hospital research into pGlu-Abeta for the treatment of Alzheimer’s disease
13 July 2015 | By Victoria White
Probiodrug is to provide funding to further investigate the potential of pGlu-Abeta antibodies for passive vaccination against Alzheimer's disease...
news
Scientists discover blood protein that may indicate risk of Alzheimer’s
24 June 2015 | By Victoria White
Scientists have identified a single blood protein that may indicate the development a disorder associated with an increased risk of Alzheimer's disease...
news
Brain inflammation targeted in first Dementia Consortium drug discovery project
22 June 2015 | By Victoria White
The Dementia Consortium is funding a new project to target the immune system in the hunt for new treatments for Alzheimer's disease...
news
Naturally occurring genetic variation gives complete resistance in prion diseases
11 June 2015 | By Victoria White
Researchers have identified a naturally occurring variant of the human prion protein that produces resistance to prion diseases such as CJD...
article
Academic drug discovery in neurodegeneration; a new approach to an ageing problem
Dementia is a global crisis with 76 million people worldwide expected to be living with the condition by 2030. Current symptomatic treatments provide modest improvements in cognition but disease-modifying therapies for diseases like Alzheimer’s – the most common cause of dementia – do not yet exist.
